NCI-H82

NCI-H82 (Small Cell Lung Cancer CDX Model) 

The NCI-H82 line was derived from a patient with small cell lung cancer (SCLC). It exhibits neuroendocrine features typical of this aggressive cancer subtype. NCI-H82 has been a cornerstone in SCLC preclinical research. Its reproducible growth ensures reliability in translational studies. 

Key Features: 

• Derived from human small cell lung cancer. 

• Neuroendocrine phenotype. 

• Highly tumorigenic in xenografts. 

• Represents aggressive SCLC biology. 

Applications: 
NCI-H82 is applied in studies of cytotoxic and targeted therapies for SCLC. Researchers use it to investigate neuroendocrine tumor biology. It supports biomarker development and drug resistance studies. Its reproducibility ensures consistent translational outcomes.